SCHEMBL4522155

SCHEMBL4522155

Cc1cc([CH]c2ccccc2)oc1C(N)=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC9A1 P19634 1/20 0.40
ALDH1A1 P00352 7/20 0.37
KDM4E B2RXH2 6/20 0.37
HPGD P15428 5/20 0.37
RAB9A P51151 4/20 0.37
MAPT P10636 5/20 0.36
LMNA P02545 3/20 0.36
NPC1 O15118 2/20 0.36
L3MBTL1 Q9Y468 3/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
GAA P10253 2/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
TTR P02766 1/20 0.34
ALOX5 P09917 1/20 0.34
PTGS1 P23219 1/20 0.34
PTGS2 P35354 1/20 0.34
NFE2L2 Q16236 1/20 0.34
POLB P06746 1/20 0.33
CYP3A4 P08684 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4523133 0.70 HDAC4 (0.49) SLC9A1ALDH1A1KDM4EHPGDRAB9A
SCHEMBL8587349 0.68 POLB (0.39) SLC9A1ALDH1A1KDM4EHPGDMAPT
SCHEMBL4523501 0.68 PARP1 (0.44) ALDH1A1KDM4EHPGDRAB9AMAPT
SCHEMBL1242320 0.64 KMT2A (0.52) ALDH1A1KDM4EHPGDMAPTLMNA
SCHEMBL3402378 0.64 NFE2L2 (0.48) ALDH1A1KDM4EHPGDRAB9AMAPT
SCHEMBL353258 0.61 MEN1 (0.49) SLC9A1ALDH1A1KDM4EMAPTLMNA
SCHEMBL9141016 0.60 BCAT2 (0.47) SLC9A1ALDH1A1KDM4ERAB9A
SCHEMBL15698564 0.60 NNMT (0.33) SLC9A1ALDH1A1KDM4EHPGDL3MBTL1
SCHEMBL29078347 0.60 ALDH1A1 (0.50) ALDH1A1KDM4EHPGDRAB9AMAPT
SCHEMBL1176914 0.60 CYP2A6 (0.60) ALDH1A1KDM4EHPGDRAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090054445-A1 Amide Substituted Quinolines ASTRAZENECA AB (SE) 2009-02-26 US claimed
US-20090054445-A1 Amide Substituted Quinolines ASTRAZENECA AB (SE) 2009-02-26 US disclosed
EP-1981882-A1 AMIDE SUBSTITUTED QUINOLINES AstraZeneca AB (SE) 2008-10-22 EP disclosed
WO-2007086799-A1 AMIDE SUBSTITUTED QUINOLINES ASTRAZENECA AB (SE) 2007-08-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054445-A1 Amide Substituted Quinolines RECQL, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, H1-0 SLC9A1 1113/4885ALDH1A1 903/4885KDM4E 1830/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.